Cancer-focused biotech startup OncoResponse raises $27M

The Seattle-based company's lead drug, OR2805, is in phase 1 trials for multiple tumor types.

Source: bizjournals.com Health Care:Physician Practices headlines - May 23, 2023 Category: American Health Authors: Rick Morgan Source Type: news